A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
Condition: Respiratory Syncytial Virus (RSV) · Sponsor: Pfizer
About this study
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
This description comes directly from the study's public registry record.
Talk to the study team
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
Locations (13)
| King George Hospital | Visakhapatnam, Andhra Pradesh, India | Not Yet Recruiting |
| BGS Global Institute of Medical Sciences (BGSGIMS) | Bangalore, Karnataka, India | Recruiting |
| Radhakrishna Multispeciality Hospital and IVF Center | Bangalore, Karnataka, India | Recruiting |
| Belagavi Institute of Medical Sciences - Belagavi | Belagavi, Karnataka, India | Recruiting |
| Suyog Hospital | Nashik, Maharashtra, India | Recruiting |
| Aakash Healthcare Private Limited | Dwarka, National Capital Territory of Delhi, India | Recruiting |
| All India Institute Of Medical Sciences | New Delhi, National Capital Territory of Delhi, India | Recruiting |
| Sir Ganga Ram Hospital | New Delhi, National Capital Territory of Delhi, India | Recruiting |
| Maharaja Agrasen Superspeciality Hospital | Jaipur, Rajasthan, India | Recruiting |
| SRM Medical College Hospital and Research Centre - Kattankulathur | Chengalpattu, Tamil Nadu, India | Recruiting |
| Chettinad Hospital and Research Institute | Kelambākkam, Tamil Nadu, India | Recruiting |
| Institute of Post Graduate Medical Education & Research, SSKM Hospital | Kolkata, West Bengal, India | Not Yet Recruiting |
+ 1 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07653100